Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes

Handelsman, 2011, American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan, Endocr Pract, 17, 1, 10.4158/EP.17.S2.1 Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413 Neeland, 2012, Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults, J Am Med Assoc, 308, 1150, 10.1001/2012.jama.11132 Wild, 2004, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 C.f.D.C.a. Prevention, 2011 Bloomgarden, 2011, Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids, J Diabetes, 3, 257, 10.1111/j.1753-0407.2011.00161.x Defronzo, 2009, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028 Mateo, 2006, Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes, Int J Clin Pract, 60, 422, 10.1111/j.1368-5031.2006.00799.x Hauber, 2009, Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents, Diabet Med, 26, 416, 10.1111/j.1464-5491.2009.02696.x Zinman, 2012, Achieving a clinically relevant composite outcome of an HbA1c of<7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme, Diabetes Obes Metab, 14, 77, 10.1111/j.1463-1326.2011.01493.x Monami, 2008, Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis, Diabetes Res Clin Pract, 79, 196, 10.1016/j.diabres.2007.08.024 Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials, Eur J Endocrinol, 160, 909, 10.1530/EJE-09-0101 Best, 2009, Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily, Diabet Med, 26, 722, 10.1111/j.1464-5491.2009.02752.x Best, 2011, Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment, Diabetes Care, 34, 314, 10.2337/dc10-1119 Bode, 2010, Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes, Diabetes Obes Metab, 12, 604, 10.1111/j.1463-1326.2010.01196.x Davies, 2011, Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin, Diabet Med, 28, 333 Secnik Boye, 2006, Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes, Health Qual Life Outcomes, 4, 80, 10.1186/1477-7525-4-80 Hermansen, 2010, Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin, Prim Care Diabetes, 4, 113, 10.1016/j.pcd.2010.04.001 Grant, 2011, Psychological and quality of life changes in patients using GLP-1 analogues, J Diabetes Complications, 25, 244, 10.1016/j.jdiacomp.2011.03.002 Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 Campbell, 2010, Distinguishing among incretin-based therapies. Patient education and self-management, J Fam Pract, 59, S28 Pratley, 2011, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int J Clin Pract, 65, 397, 10.1111/j.1742-1241.2011.02656.x Aroda, 2012, Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review, Clin Ther, 34, 1247, 10.1016/j.clinthera.2012.04.013 Campbell, 2010, Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies, J Fam Pract, 59, S10 Cryer, 2008, The barrier of hypoglycemia in diabetes, Diabetes, 57, 3169, 10.2337/db08-1084 Cryer, 2008, Hypoglycemia: still the limiting factor in the glycemic management of diabetes, Endocr Pract, 14, 750, 10.4158/EP.14.6.750 Alvarez-Guisasola, 2010, Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study, Health Qual Life Outcomes, 8, 86, 10.1186/1477-7525-8-86 Evans, 2012 Budnitz, 2011, Emergency hospitalizations for adverse drug events in older Americans, N Engl J Med, 365, 2002, 10.1056/NEJMsa1103053 Liu, 2012, Economic burden of hypoglycemia in patients with type 2 diabetes, Expert Rev Pharmacoecon Outcomes Res, 12, 47, 10.1586/erp.11.87 Amiel, 2008, Hypoglycaemia in type 2 diabetes, Diabet Med, 25, 245, 10.1111/j.1464-5491.2007.02341.x Kushner, 2010, Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus, Diabetes Metab Syndr Obes, 3, 49, 10.2147/DMSOTT.S10013 Zoungas, 2010, Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 363, 1410, 10.1056/NEJMoa1003795 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540 Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413 Ismail-Beigi, 2011, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials, Ann Intern Med, 154, 554, 10.7326/0003-4819-154-8-201104190-00007 Deusenberry, 2012, Hypoglycemia in hospitalized patients treated with sulfonylureas, Pharmacotherapy, 32, 613, 10.1002/j.1875-9114.2011.01088.x Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2012; 10.1111/dom.12025 [Epub ahead of print] Rodbard, 2010, Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes, J Am Med Assoc, 304, 405, 10.1001/jama.2010.1021 E. Society, Understanding obesity in America. http://www.obesityinamerica.org/understandingObesity/index.cfm Campbell, 2010, Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies, J Fam Pract, 59, S5 Vilsboll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, Br Med J, 344, d7771, 10.1136/bmj.d7771 Fonseca, 2011, Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus, Am J Cardiol, 108, 52B, 10.1016/j.amjcard.2011.03.016 Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther. 2012; 10.1111/cdr.12000 [Epub ahead of print] Marso, 2011, Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies, Diab Vasc Dis Res, 8, 237, 10.1177/1479164111408937 Ratner, 2011, Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes, Cardiovasc Diabetol, 10, 22, 10.1186/1475-2840-10-22 Best, 2011, Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database, Diabetes Care, 34, 90, 10.2337/dc10-1393 Bergenstal RM, Li Y, Porter TK, Weaver C, Han J. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors, and a composite index of an HbA1c<7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab 2012; 10.1111/dom.12026 [Epub ahead of print] 2005, Med Lett Drugs Ther, 47, 45 Drucker, 2008, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet, 372, 1240, 10.1016/S0140-6736(08)61206-4 Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374, 39, 10.1016/S0140-6736(09)60659-0 Gallwitz, 2010, Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus, Drug Saf, 33, 87, 10.2165/11319130-000000000-00000 Bain, 2010, Clinical experience with liraglutide, Int J Clin Pract, 44, 10.1111/j.1742-1241.2010.02494.x 2012, Med Lett Drugs Ther, 54, 21 2010, Med Lett Drugs Ther, 52, 25 Drucker, 2011, The safety of incretin-based therapies—review of the scientific evidence, J Clin Endocrinol Metab, 96, 2027, 10.1210/jc.2011-0599 Dore, 2009, Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide, Curr Med Res Opin, 25, 1019, 10.1185/03007990902820519 Wall, 2010, High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data, Am J Med Sci, 339, 401, 10.1097/MAJ.0b013e3181d430ad Rocco, 2012, KDOQI clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005 Linnebjerg, 2007, Effect of renal impairment on the pharmacokinetics of exenatide, Br J Clin Pharmacol, 64, 317, 10.1111/j.1365-2125.2007.02890.x Davidson, 2010, Mild renal impairment has no effect on the efficacy and safety of liraglutide, Endocr Pract, 1 Jacobsen, 2009, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide, Br J Clin Pharmacol, 68, 898, 10.1111/j.1365-2125.2009.03536.x Hegedus, 2011, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide, J Clin Endocrinol Metab, 96, 853, 10.1210/jc.2010-2318 Fineman, 2012, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes Obes Metab, 14, 546, 10.1111/j.1463-1326.2012.01561.x Buse, 2011, Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials, J Clin Endocrinol Metab, 96, 1695, 10.1210/jc.2010-2822